Compare · MRK vs VIRX
MRK vs VIRX
Side-by-side comparison of Merck & Company Inc. (MRK) and Viracta Therapeutics Inc. (VIRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and VIRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $385.99B, about 4292.5x VIRX ($89.9M).
- MRK has hit the wire 17 times in the past 4 weeks while VIRX has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 2 for VIRX).
- Company
- Merck & Company Inc.
- Viracta Therapeutics Inc.
- Price
- -
- -
- Market cap
- $385.99B
- $89.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2005
- News (4w)
- 17
- 0
- Recent ratings
- 25
- 2
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Viracta Therapeutics Inc.
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff-by-the-Sea, California.
Latest MRK
- Merck downgraded by RBC Capital Mkts with a new price target
- Merck upgraded by Morgan Stanley with a new price target
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
- EVP, Access, Policy & Comms Guindo Chirfi sold $1,350,000 worth of shares (10,000 units at $135.00), decreasing direct ownership by 21% to 36,613 units (SEC Form 4)
- EVP, General Counsel Zachary Jennifer exercised 54,927 shares at a strike of $109.78 and sold $10,718,495 worth of shares (80,315 units at $133.46), decreasing direct ownership by 36% to 45,509 units (SEC Form 4)
- EVP&Pres, Merck Animal Heallth Deluca Richard R. sold $5,942,369 worth of shares (45,320 units at $131.12), decreasing direct ownership by 29% to 110,167 units (SEC Form 4)
- Merck upgraded by Daiwa Securities with a new price target
- EVP&Pres, Merck Animal Heallth Deluca Richard R. sold $788,773 worth of shares (6,050 units at $130.38), decreasing direct ownership by 4% to 155,487 units (SEC Form 4)
- EVP & Pres. MMD Maraldo David R. exercised 18,706 shares at a strike of $82.25 and sold $2,407,797 worth of shares (18,706 units at $128.72) (SEC Form 4)
- EVP,Chief Info&Digital Officer Williams David Michael exercised 52,847 shares at a strike of $74.49 and sold $6,805,145 worth of shares (52,847 units at $128.77), increasing direct ownership by 0.00% to 31,716 units (SEC Form 4)
Latest VIRX
- Viracta Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Viracta Therapeutics Announces Wind Down of Operations
- Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Viracta Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation, Financial Statements and Exhibits
- Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Viracta Therapeutics Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update, Other Events, Financial Statements and Exhibits
- Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
- Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Director Royston Ivor converted options into 25,219 shares, increasing direct ownership by 3% to 839,741 units (SEC Form 4)
- Director Pomerantz Roger converted options into 9,034 shares, increasing direct ownership by 8% to 126,478 units (SEC Form 4)